EVRYSDI DIN 02514931
Health Canada record
| Active ingredient(s) | RISDIPLAM 0.75 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | M09AX10 RISDIPLAM |
| Original market date | 19-May-2021 |
| Current status date | 19-May-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RISDIPLAM
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02560747 | EVRYSDI | HOFFMANN-LA ROCHE LIMITED | Tablet | RISDIPLAM 5 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 25680 | 2021-04-14 | New Drug Submission (NDS) |
International API supply for RISDIPLAM
6 active FDA Drug Master Files.
Request a quote for EVRYSDI